Unicycive Therapeutics Inc stock is traded at $3.49, with a volume of 107,169. It is up +0.29% in the last 24 hours and down -17.49% over the past month. Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Previous Close:
$3.48
Open:
$3.46
24h Volume:
107,169
Relative Volume:
0.09
Market Cap:
$97.21M
Revenue:
$675.00K
Net Income/Loss:
-$39.95M
P/E Ratio:
-
EPS:
-$2.06
Net Cash Flow:
-$28.67M
1W Performance:
-6.68%
1M Performance:
-17.49%
6M Performance:
-57.07%
1Y Performance:
-22.10%
1-Day Range:
$3.45$3.59
1-Week Range:
$3.33$3.79
52-Week Range:
$3.33$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
650-384-0642Address
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS